Modern capabilities in diagnosis and treatment of neurotrophic keratopathy

Brzheskiy, V.V.; Popov, VI; Ефимова, Е.Л.; Голубев, С. Ю.

doi:10.17116/oftalma2022138061123

Cited by 5 publications

(1 citation statement)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, trigeminal nerve damage can affect tear lm production through a loss of functioning in the protective sensory-mediated re exes such as the tear gland re ex and blinking. The intact interaction between tear lm, epithelium layer, and sensory innervation is essential for the stability of the epithelium (10,(14)(15)(16)(17). NK can cause temporary or even permanent visual dysfunction as a result of the inability to resynthesize the corneal epithelium, the enzymatic deterioration of stroma, and the decrease of tear production.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of plasma rich in growth factors (PRGF) in stage 1 neurotrophic keratitis

Ghalibafan,

Osei,

Amescua

et al. 2023

Eye

View full text Add to dashboard Cite

Background/Aims: Neurotrophic keratitis (NK) is a neurodegenerative disease that can lead to corneal hypoesthesia, decreased tear production, and epitheliopathy. Based on the severity of ocular surface damage, NK is classi ed into 3 stages. Stage 1 NK is characterized by super cial punctate keratopathy, tear lm instability, and reduced corneal sensation. The therapeutic e cacy of PRGF eye drops for NK stages 2 and 3 has been previously reported. In this study, we evaluated the e cacy and safety of autologous PRGF eye drops in improving corneal sensitivity and other ocular surface clinical signs in patients with stage 1 NK. Methods: Retrospective chart reviewResults: 26 eyes of 15 stage 1 NK patients (seven males, eight females), aged 76.3 ± 12.1 years, were included in the study. The mean treatment duration was 2 ± 1.8 months. With PRGF treatment, corneal sensitivity increased from 2.8 to 4.5 cm in 53.8% (14/26) (p < 0.01), TBUT increased from 3.6 to 5.0 s in 69.2% (18/26) (p < 0.01), and Schirmer score increased from 13.7 to 16.8 mm in 80.7% (21/26) of treated eyes (p < 0.01). Similarly, an improvement in corneal staining (punctate epithelial erosions) and MMP-9 levels was seen in 80.7% (n = 21) and 65.4% (n = 17) of treated eyes, respectively. BCVA improvement was seen in 26.9% of treated eyes (n = 7).Conclusions:This study demonstrates the effective role of PRGF therapy in recovering corneal sensation and tear lm function and in the healing of corneal erosions in stage 1 NK patients.

show abstract